Study shows longer arrhythmia detection window reduces shocks for medtronic implantable defibrillator patients

Medtronic, 05/11/2012

Medtronic, Inc. announced results from the first and only clinical trial to show that Medtronic cardiac devices can safely extend detection time before triggering therapy in primary and secondary prevention patients. The ADVANCE III study, presented today as a late–breaking presentation at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, evaluated patients with implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy with defibrillation (CRT–D), and found devices programmed with longer duration (increased number of intervals) to detect arrhythmias provided therapy (shocks and anti–tachycardia pacing, ATP) only when needed and without increased risk to patients.

Print Article Summary Cat 2 CME Report